CAH

CAH

USD

Cardinal Health Inc. Common Stock

$158.600+3.500 (2.257%)

Reaalajas hind

Healthcare
Medical Distribution
Ameerika Ühendriigid

Hinnagraafik

Loading Chart...

Põhinäitajad

Turunäitajad
Ettevõtte fundamentaalnäitajad
Kauplemisstatistika

Turunäitajad

Avatud

$155.100

Kõrge

$159.078

Madal

$152.080

Maht

2.16M

Ettevõtte fundamentaalnäitajad

Turukapitalisatsioon

37.9B

Tööstusharu

Medical Distribution

Riik

United States

Kauplemisstatistika

Keskmine maht

2.42M

Börs

NYQ

Valuuta

USD

52 nädala vahemik

Madal $93.17Praegune $158.600Kõrge $159.078

Tehisintellekti analüüsiaruanne

Viimati uuendatud: 26. mai 2025
Tehisintellekti loodudAndmeallikas: Yahoo Finance, Bloomberg, SEC

CAH: Cardinal Health Inc. Common Stock – What the Latest Signals Are Saying

Stock Symbol: CAH Generate Date: 2025-05-26 12:56:15

Let's break down what's been happening with Cardinal Health and what the numbers might suggest for its path forward.

Recent News Buzz: A Positive Current

The news flow around Cardinal Health lately has been pretty upbeat. We're seeing a clear positive sentiment. For starters, the company's board just approved an increase to its quarterly dividend, bumping it up to $0.5107 per share. That's a direct benefit to shareholders and usually signals confidence from management.

Then there's the analyst community. Morgan Stanley, UBS, and Baird have all maintained "Overweight" or "Buy" ratings, and crucially, they've raised their price targets. We're talking targets now ranging from $166 to $170. This tells us that professional analysts see more room for the stock to grow.

Adding to this, Cardinal Health reported its third-quarter fiscal year 2025 results, and while revenues were flat year-over-year at $54.9 billion, they also raised their fiscal year 2025 outlook. This is a big deal; it means they expect to perform better than previously thought for the full year. The only outlier news was about Carlisle Companies' leadership changes, which isn't directly related to CAH and can be ignored for our purposes here.

So, the overall vibe from the news is definitely positive, driven by dividend hikes, analyst upgrades, and an improved company outlook.

Price Check: Climbing Higher

Looking at the stock's recent journey over the last 30 days, Cardinal Health has been on a noticeable upward trend. Back in late February, it was hovering around the $126-$127 mark. Fast forward to early May, and we saw a significant jump, especially around May 1st, when it moved from the $140 range to over $145, then quickly to nearly $150 by May 2nd. This aligns perfectly with the positive news about their earnings report and analyst upgrades coming out around that time.

The stock has continued to climb, with the last recorded close on May 23rd at $152.75. This is a solid move up from its earlier levels. The trading volume has also seen some spikes, like the 5.4x average surge mentioned in the recommendation data, indicating strong buying interest at times.

Now, let's compare this to the AI's predictions. The AI model from AIPredictStock.com suggests a flat movement for today (0.00%), but then a notable jump of 2.55% for the next day, followed by a smaller gain of 0.21% the day after. This aligns with the recent upward momentum and the positive sentiment.

Outlook & Ideas: Riding the Momentum?

Putting it all together, the current situation for Cardinal Health seems to lean quite favorably for potential buyers. The strong positive news sentiment, coupled with a clear upward trend in price and AI predictions pointing to continued gains, paints a promising picture.

Given the current price of $152.75 and the AI's prediction of a 2.55% rise tomorrow, along with analyst targets reaching up to $170, there appears to be room for growth.

Potential Entry Consideration: If you're looking to get in, the current price around $152.75 could be a reasonable entry point, especially considering the AI's forecast for the next couple of days. The recommendation data also suggests entry points around $152.47 to $153.00, which is right in this ballpark. This level seems to be acting as a strong support, as indicated by the "Current Price is extremely close to support level ($152.71), suggesting strong buying opportunity" note.

Potential Exit/Stop-Loss Consideration: For managing risk, a stop-loss around $137.47 is suggested by the recommendation data. This level is well below recent lows and would help protect against a significant downturn if the positive trend reverses unexpectedly. On the upside, a potential take-profit target could be around $155.79, as indicated, or even higher towards the analyst targets of $166-$170 if the momentum truly builds.

Company Context: Healthcare Backbone

It's worth remembering that Cardinal Health is a major player in the healthcare sector, specifically in medical distribution. They provide essential services and products to hospitals, pharmacies, and other healthcare providers. This makes them a foundational part of the healthcare system. Their revenue growth being flat, as noted in the fundamental analysis, is something to keep an eye on, but the improved outlook suggests they're finding ways to optimize within their stable industry. The dividend increase and analyst confidence suggest that despite flat revenue, profitability or future prospects are looking good.


Disclaimer: This analysis is for informational purposes only and should not be considered financial advice. Investing in stocks involves risks, and you could lose money. Always conduct your own thorough research or consult with a qualified financial professional before making any investment decisions.

Seotud uudised

PR Newswire

Cardinal Health Details Momentum and Updated Long-Term Value Creation Plans at Investor Day

Cardinal Health (NYSE: CAH) today will host an Investor Day beginning at 9:00 a.m. ET, where management will detail its growth strategies to maximize ...

Vaata rohkem
Cardinal Health Details Momentum and Updated Long-Term Value Creation Plans at Investor Day
Analyst Upgrades

Cardinal Health Analyst Flags Fading Scale Gap, Sees Rising Edge in Specialty Growth

BofA's Lutz raised Cardinal Health's target to $170, citing specialty growth momentum and a shrinking scale gap as key upside drivers.

Vaata rohkem
Cardinal Health Analyst Flags Fading Scale Gap, Sees Rising Edge in Specialty Growth
Analyst Upgrades

B of A Securities Maintains Buy on Cardinal Health, Raises Price Target to $170

B of A Securities analyst Michael Cherny maintains Cardinal Health with a Buy and raises the price target from $165 to $170.

Vaata rohkem
B of A Securities Maintains Buy on Cardinal Health, Raises Price Target to $170
PR Newswire

Citius Oncology Enters into Distribution Services Agreement with Cardinal Health

Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq:...

Vaata rohkem
Citius Oncology Enters into Distribution Services Agreement with Cardinal Health
PR Newswire

Cardinal Health launches new medical device for the continuous monitoring of three essential vital signs in one system

Cardinal Health (NYSE: CAH) announced today the U.S. launch of its multi-parameter, single-patient use monitoring cable and lead wire system that...

Vaata rohkem
Cardinal Health launches new medical device for the continuous monitoring of three essential vital signs in one system
Analyst Upgrades

Wells Fargo Upgrades Cardinal Health to Overweight, Raises Price Target to $179

Wells Fargo analyst Stephen Baxter upgrades Cardinal Health from Equal-Weight to Overweight and raises the price target from $136 to $179.

Tehisintellekti ennustusBeta

Tehisintellekti soovitus

Tõusev

Uuendatud kell: 12. juuni 2025, 15:25

LangevNeutraalneTõusev

67.5% Kindlus

Risk ja kauplemine

Riskitase1/5
Madal risk
Sobib
Konservatiivne
Kauplemisjuhend

Sisenemispunkt

$153.14

Võta kasum

$156.59

Peata kahjum

$138.17

Põhitegurid

PDI 5.0 on MDI 3.6 kohal ADX-iga 14.8, mis viitab tõusutrendile
Praegune hind on tugitasemele ($153.12) äärmiselt lähedal, mis viitab tugevale ostuvõimalusele
Kauplemismaht on 17.2x keskmisest (15,971), mis viitab äärmiselt tugevale ostusurvele
MACD -0.0618 on signaalijoone -0.0996 kohal, mis viitab tõusvale ristumisele

Püsi kursis

Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.